Abstract: Orthogonally protected 3?-amino nucleoside monomers and efficient methods for their synthesis are described. The methods employ selective protection of the 3?-amino group in the presence of the unprotected nucleoside base.

Abstract: The present invention relates to a method for purification of hemopexin and haptoglobin and provides a method in which a solution containing hemopexin and haptoglobin is titrated to a range of specific pH values without a step of precipitating haptoglobin by salt addition, followed by separating and purifying hemopexin and haptoglobin individually.

Abstract: The disclosure relates to chromatography ligands, e.g., chromatography ligands comprising at least two binding units and at least one spacer domain, wherein each binding unit comprises one or two immunoglobulin binding domains.

Abstract: The present invention provides a polypeptide for preventing or treating idiopathic pulmonary fibrosis, which is synthesized by linking 9 to 10 amino acids together and comprises an amino acid sequence consisting of arginine (R, Arg)-glycine (G, Gly)-aspartic acid (D, Asp)-valine (V, Val)-phenylalanine (F, Phe)-proline (P, Pro)-serine (S, Ser)-tyrosine (Y, Tyr)-threonine (T, Thr). Accordingly, the polypeptide for preventing or treating idiopathic pulmonary fibrosis according to the present invention may restore lung function to normal by fundamentally treating lung tissue that has undergone fibrosis due to idiopathic pulmonary fibrosis, and furthermore, may delay or prevent the onset of idiopathic pulmonary fibrosis.

Abstract: An artificial short interfering peptide for the phosphorylation substrate of DAPK1 and its potential pharmaceutical applications is provided. In the field of peptide drug development, the peptide can be used in preparation of drugs for prevention and treatment of ischemic stroke, as well as the drugs for the disease that based on the same mechanism, such as traumatic brain injury, spinal cord injury, neonatal hypoxic-ischemic encephalopathy, depression, autism and neurodegenerative diseases like multiple sclerosis. Alzheimer's disease, amyotrophic lateral sclerosis, Parkinson's disease, and Huntington's disease.

Abstract: The disclosures herein relate to the fields of cell biology and the modulation of cellular mechanisms controlling cell viability, cell proliferation, and metabolic processes. More specifically disclosed herein are peptides effective to modulate cellular mechanisms controlling cell viability, cell proliferation, and metabolic processes, including cell signaling associated with aberrant cellular proliferation and malignancy. Also disclosed herein are peptides effective in modulating cellular mechanisms controlling cell viability, treating metabolic diseases, and as cytoprotective agents.

Abstract: Provided are polypeptides that have at least about 95% but less than 100% sequence identity to SEQ ID NO: 2, optionally wherein the polypeptide has an amino acid sequence as set forth in SEQ ID NO: 4, with the proviso that the polypeptide does not have 100% sequence identity to SEQ ID NO: 2.

Abstract: Disclosed are a self-assembled nanoparticle containing a gB protein of an EB virus and a preparation method and use thereof The self-assembled nanoparticle comprises a first polypeptide and a second polypeptide; the first polypeptide comprises the gB protein and a first vector subunit, the second polypeptide comprises a second vector subunit; the first vector subunit is I53-50A1, and the second vector subunit is I53-50B.4PT1. In the self-assembled nanoparticle provided herein, the gB protein of the EB virus is displayed on the surface of the nanoparticle for the first time. The particle size of the self-assembled nanoparticle is larger than that of the antigen gB, and the chemical stability of the self-assembled nanoparticle is higher than that of the antigen gB, and the binding capacity with the neutralizing antibody of the self-assembled nanoparticle are higher than that of the antigen gB.

Abstract: The disclosure provides mutant Brassica plants that have increased locules and seed production relative to native wild-type plants. Such plants include a point mutation in the clavata 1 gene (CLV1), such as a G->A substitution at position 1745 of the Brassica rapa coding sequence, which leads to an S582N substitution in the protein sequence. Equivalent substitutions can be made in any Brassicaceae coding/protein sequence. Also provided are methods of using such plants in breeding programs, as well as parts of such plants (such as seeds), and methods of making commodity products from such plants (e.g., oil). Also provided are mutant CLV1 sequences. Brassica plants harboring the disclosed CLV1 mutation can include other desirable traits, such as herbicide tolerance.

Abstract: The described invention relates to tick chemokine binding polypeptides (tick CKBPs, typically tick Evasins) including hybrid CKBPs based on sequences from two or more tick CKBPs, and the uses of such polypeptides in inhibition of chemokines or detection of chemokine expression and inflammation.

Abstract: The present invention relates to an IF1 protein-derived peptide and a medicinal use thereof, in which the peptide suppresses appetite and inhibits lipid accumulation and differentiation of adipocytes in an obese animal model, and promotes insulin secretion and improves glucose tolerance in a diabetic animal model. Therefore, the present invention can be usefully used for anti-obesity and anti-diabetic purposes.

Abstract: The present invention provides novel peptides and homologues thereof. The peptides of the invention comprise (i) a T-cell epitope of an antigen (self or non-self) with a potential to trigger an immune reaction presented by a class II major histocompatibility complex (MHC) determinant and recognised by CD4+ T cell more specifically of an allergen or auto-antigen, coupled, optionally through the use of a linker to (ii) an amino acid sequence having a reducing activity, such as a thioreductase sequence. The peptides of the invention have been shown to be useful a medicine, more in particular for the prevention or treatment of immune disorders, more specifically of allergic disorders or autoimmune diseases. The present invention thus provides for the use of said peptides for the manufacture of a medicament for the prevention or treatment of an immune disorder and further provides for methods of treatment or preventing immune disorders by using said peptides.

Abstract: The present invention relates generally to a recombinant protein, compositions comprising such recombinant protein, and to methods for producing such recombinant protein and compositions.

Abstract: Methods and compositions involving synthetic immodulin peptides and helper molecules. The peptides exhibit new and surprising biological activities, such as co-stimulation of macrophage and myogenic cell differentiation markers. Methods are provided N by which peptide is contacted with one or more myeloid precursor cell populations, thereby increasing the abundance of CD169+, CCL22+, Clec4A, Clec9a+, and Clec 12a+ monocyte lineages which play important roles in cross presentation, post-apoptotic clearance, autoimmunity, and programmatic tissue regeneration, notably in contexts of tissue stress, insult and degeneration. The disclosed methods and compositions enable concurrent regeneration of diverse cellular elements in tissue where collaborating myeloid and non-myeloid lineages are located together in a living tissue following the contacting steps.

Abstract: The present disclosure provides in one aspect a construct comprising the R2 region of FGF23. In other embodiments, the construct functions as a FGF23 antagonist by blocking FGF23 binding to ?-Klotho and cell signaling via FGFR activation. In yet other embodiments, the construct prevents FGFR activation. In yet other embodiments, the construct of the present disclosure can be used to treat diseases or disorders related to FGF23 dysregulation and/or overexpression, such as but not limited to phosphate metabolism disorders.

Abstract: The present disclosure provides conjugates of polypeptides comprising nanobody and FGF21 linked by a polypeptide linker. The present disclosure further provides conjugates of polypeptides comprising GLP-1, nanobody, and FGF21 linked by two polypeptide linkers respectively. Pharmaceutical compositions comprising the same and methods of treating diseases are also provided.

Abstract: The present invention relates to the field of biotechnology and medicine, in particular to an immunocytokine for activating the human IL-10R? receptor. The invention further relates to nucleic acids encoding said immunocytokine, expression vectors, host cells and methods for producing same, methods for producing the immunocytokine, pharmaceutical compositions comprising the above immunocytokine, pharmaceutical compositions comprising the above immunocytokine and other therapeutically active compounds, methods for treating an oncological disease and the uses of the immunocytokine or pharmaceutical compositions thereof for treating an oncological disease.

Abstract: The technology described herein is directed to pharmaceutical compositions comprising at least one Scg2 neuropeptide, as well as cell culture media or kits comprising such Scg2 neuropeptides. Also described herein are nucleic acids, vectors, or viral vectors encoding at least one Scg2 neuropeptide. In further aspects, described herein are methods of treating a memory-associated disorder, a learning disability, a neurodegenerative disease or disorder, or epilepsy with a pharmaceutical composition, nucleic acid, vector, or viral vector as described herein. In further aspects, described herein are detection methods of memory-associated analytes, such as Scg2 neuropeptides.

Abstract: Anti-angiogenic agents or polypeptides have an amino acid segment substantially similar to domain one of CD2. The polypeptide has a ?-sheet formed by two segments. Methods of using such agents and polypeptide are also included.

Abstract: The present disclosure provides antigen-presenting polypeptides, including single-chain antigen-presenting polypeptides and multimeric antigen-presenting polypeptides. The present disclosure provides nucleic acids comprising nucleotide sequences encoding antigen-presenting polypeptides of the present disclosure, as well as cells genetically modified with the nucleic acids. An antigen-presenting polypeptide of the present disclosure is useful for modulating activity of a T cell. Thus, the present disclosure provides methods of modulating activity of a T cell.

Abstract: The present disclosure provides improved compositions for adoptive T cell therapies targeting BCMA for treating, preventing, or ameliorating at least one symptom of a B cell related condition. The present disclosure also relates to adoptive T cell therapies for dual targeting of BCMA and a B cell antigen for treating, preventing, or ameliorating at least one symptom of a B cell related condition.

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

Abstract: The present disclosure provides T-cell modulatory multimeric polypeptides (TMMPs) that comprise an immunomodulatory polypeptide, class I HLA polypeptides (a class I HLA heavy chain polypeptide and a ?2 microglobulin polypeptide), a peptide that presents an epitope to a T-cell receptor, and a tumor-targeting polypeptide. A TMMP is useful for modulating the activity of a T cell, and for modulating an immune response in an individual.

Abstract: Provided are methods for activating an antigen-presenting cell and eliciting an immune response by inducing pattern recognition receptor activity, and CD40 activity. Also provided are methods for activating an antigen-presenting cell and eliciting an immune response by inducing CD40 activity without prostaglandin E2. Also provided are methods for activating an antigen-presenting cell and eliciting an immune response by inducing an inducible chimeric molecule comprising a region of a pattern recognition receptor or an adaptor thereof.

Abstract: The present invention relates to antibodies, and antigen binding fragments thereof, that bind to the F-protein (fusion protein) of metapneumovims (MPV). The antibodies, and antigen binding fragments thereof, neutralize infection of MPV. The invention also relates to nucleic acids that encode, and to cells that express such antibodies and antibody fragments. In addition, the invention relates to the use of the antibodies and antibody fragments in methods for detecting and checking an MPV antigen as well as in the diagnosis, treatment and prevention of MPV infection.

Abstract: The present invention relates to immunogenic compositions comprising RSV F protein, methods for preparing compositions that contain RSV F protein ecto-domain polypeptides, and to certain engineered RSV F proteins and nucleic acids that encode the engineered RSV F proteins. Compositions prepared using the methods can contain RSV F protein ecto-domain polypeptides in a predominant or single desired form and conformation. The invention also relates to methods for inducing an immune response to RSV F.

Abstract: Antibodies that bind to HIV gp120 and neutralize HIV are disclosed. Also disclosed are methods of using such antibodies alone or in combination with other therapeutic agents to treat or prevent HIV infection.

Abstract: The present disclosure relates generally to methods of preventing, reducing risk of developing, or treating epilepsy, comprising administering to a subject an inhibitor of the classical complement pathway.

Abstract: Provided is a use of a regulator of ITPRIPL1 in the preparation of a drug that regulates immune responses or resists tumors, the regulator being used to increase or decrease the expression or function of the ITPRIPL1 gene or protein in an organism. Also provided is a pharmaceutical composition, which comprises the regulator used in the use. Also provided are an isolated ITPRIPL1 recombinant protein and an antibody that recognizes and binds to the ITPRIPL1. On the basis of the principle that an ITPRIPL1 protein binds to CD3? and NRP2 receptors to regulate the functions of different immune cells, and then participates in the regulation of immune responses and a process of immune evasion of a tumor, it is confirmed that a regulator of ITPRIPL1 may be used to prepare a drug or a pharmaceutical composition, and may be applied to suppress tumors, autoimmune disease, transplant rejection, allergies and infections and other diseases.

Abstract: Provided herein are antibodies that specifically bind Tau and methods of using the same.

Abstract: The disclosure is directed to a monoclonal antibody. or an antigen-binding fragment thereof. directed against fibrils of amyloid beta (A?) peptides, as well as a method of treating and diagnosing neurodegenerative diseases using the monoclonal antibody.

Abstract: Antibodies that specifically bind to complement factor D in a pH sensitive manner, are described, as well as methods of making and using such antibodies.

Abstract: The disclosure provides, in various embodiments, polypeptides (e.g., antibodies and antigen binding fragments thereof) that specifically bind to a thymic stromal lymphopoietin (TSLP) (e.g., a full-length human TSLP). The disclosure also provides, in various embodiments, fusion proteins comprising one or more of the polypeptides, polynucleotides encoding the polypeptides, vectors and host cells suitable for expressing the polypeptides, and methods for treating a TSLP-associated disease or condition.

Abstract: Fully human monoclonal Abs includes (i) an antigen-binding variable region that exhibits very high binding affinity for IL-1? and (ii) a constant region that is effective at both activating the complement system though C1q binding and binding to several different Fc receptors.

Abstract: Obesity and/or diabetes are treated by partially inhibiting circulating leptin in a person in need thereof.

Abstract: The invention provides tumor specific anti-CLDN18.2 antibodies or fragments thereof. The antibodies or fragments thereof exhibit increased binding to tumor tissue expressing CLDN 18.2 over healthy tissue expressing CLDN18.2. Further, the antibodies do not exhibit cross-reactivity to CLDN18.1. The invention also provides nucleic acids, vectors, host cells and medical uses.

Abstract: An isolated antibody, or an antigen-binding portion thereof, targeting Claudin 18.2. The antibody can be single domain antibody, or its monomeric variable domain can be fused with a heavy chain constant region, such as a human IgG1 Fc. Pharmaceutical compositions including the antibody, and methods of use of the pharmaceutical compositions in the treatment of diseases are also provided.

Abstract: Provided herein are retinoid X receptor alpha binders that specifically bind to an epitope of a retinoid X receptor alpha, wherein the epitope comprises a phosphorylated serine at position 56 or 70. Also provided herein are retinoid X receptor alpha/polo-like kinase 1 modulators that inhibit the interaction of a polo-like kinase 1 with a retinoid X receptor alpha comprising a phosphorylated serine at position 56 or 70.

Abstract: Provided in the present disclosure are anti-P-cadherin antibodies, the nucleic acid molecules encoding the anti-P-cadherin antibodies, expression vectors and host cells used for the expression of anti-P-cadherin antibodies. The disclosure further provides the methods for validating the function of antibodies and uses thereof.

Abstract: The present invention relates to an optic nerve protecting agent containing an anti-low density lipoprotein receptor-related protein 1 (LRP1) antibody or an anti-LRP1 antibody fragment.

Abstract: Methods and compositions are provided for the treatment of cancer with a targeted therapy in combination with radiation. Administration of an effective dose or series of doses of a CD47 blocking agent, i.e. an agent that blocks the interaction between CD47 and SIRP?, is combined with radiation therapy to provide for an abscopal effect. In some embodiments the cancer is a metastatic cancer, or a cancer with a high likelihood of metastasis.

Abstract: Provided herein are compositions, methods and uses involving antibodies that specifically bind to signal regulatory protein-? (SIRP?) and modulate the activity of SIRP?.

Abstract: The present invention relates to an antibody specific for CD47 and uses thereof, and more particularly, to an antibody that specifically binds to CD47, a chimeric antigen receptor comprising the antibody, and a pharmaceutical composition comprising the same for preventing or treating diseases mediated by CD47-expressing cells. In the present invention, antibodies that more specifically binds to CD47 were screened to establish 7 new types of antibodies (7C7, 5H4, 5A4, 4E12, 3H3, 3A5, 1E7), and it was confirm that the novel antibodies can specifically binds with CD47 antigen. In addition, since it was confirmed that the production of a chimeric antigen receptor (CAR) targeting CD47 is possible using the established antibody, the CD47-specific antibody of the present invention and the chimeric antigen receptor prepared using the same can be applied for use in preventing or treating a cancer or tumor expressing CD47.

Abstract: The present invention relates to antibodies having specificity to Nectin-4 and uses thereof.

Abstract: Provided are an antigen binding protein capable of binding to PD-1 and a fusion protein thereof, and corresponding preparation method therefor and the use thereof. The fusion protein is capable of targeting PD-1 and CD73.

Abstract: The disclosure provides a method for immunotherapy of a subject afflicted with cancer, comprises administering to the subject a composition comprising a therapeutically effective amount of an antibody that inhibits signaling from the PD-1/PD-L1 signaling pathway. This disclosure also provides a method for immunotherapy of a subject afflicted with cancer comprising selecting a subject that is a suitable candidate for immunotherapy based on an assessment that the proportion of cells in a test tissue sample from the subject that express PD-L1 on the cell surface exceeds a predetermined threshold level, and administering a therapeutically effective amount of an anti-PD-1 antibody to the selected subject. The invention additionally provides rabbit mAbs that bind specifically to a cell surface-expressed PD-L1 antigen in a FFPE tissue sample, and an automated IHC method for assessing cell surface expression in FFPE tissues using the provided anti-PD-L1 Abs.

Abstract: The invention provides means and methods for inhibiting a biological activity of cells. In one embodiment the invention is concerned with a method of inhibiting a biological activity in a first or second cell mediated by the binding of two membrane proteins that are binding partners for each other. The mentioned biological activity is inhibited by providing the cells with an antibody or antibody like molecule that can bind to each of the mentioned binding partners and the binding blocks the binding of the two binding partners thereby inhibiting the mentioned biological activity.

Abstract: The present invention relates to novel proteins containing heterodimeric antibody Fc such as bispecific antibodies, and novel methods for preparing such proteins.

Abstract: The present disclosure is directed to a protein binding agent, or an antibody or an antigen-binding fragment thereof, which binds to a programmed death-1 (PD-1) protein. The present disclosure further provides a polynucleotide sequence encoding the protein binding agent, the antibody or the antigen-binding fragment thereof, a vector comprising the polynucleotide sequence, or a host cell comprising the vector. Also, the present disclosure provides a pharmaceutical composition or a kit, which comprises the protein binding agent, the antibody or the antigen-binding fragment thereof.

Abstract: The invention provides means, methods, and compositions of matter useful for enhancing tumor response to checkpoint inhibitors. In one embodiment, the invention teaches utilization of extracorporeal apheresis, specifically removal of various tumor derived, or tumor microenvironment derived immunological “blocking factors”. In one embodiment the invention provides the removal of soluble TNF-alpha receptors (sTNF-Rs) as a means of augmenting efficacy of immune checkpoint inhibitors. In one specific embodiment removal of sTNF-Rs is utilized to enhance efficacy of inhibitors of the PD-1/PD-L1 pathway, and/or the CD28/CTLA-4 pathway.